As one of two National Biocontainment Laboratories constructed under grants awarded by the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH), the Galveston National Laboratory (GNL) enables progress in our understanding of the fundamental mechanisms underlying the spread of infectious diseases and the pathogenesis of the diseases they cause.

The National Emerging Infectious Diseases Laboratories (NEIDL) is one of two National Biocontainment Laboratories constructed under a grant from the National Institute of Allergy and Infectious Diseases. The mission of the NEIDL is to generate and translate fundamental knowledge on high priority emerging infectious diseases for the benefit of the public health, locally, nationally and globally.

The Combating Antibiotic-Resistant Bacteria Interdisciplinary Research Units (CARBIRUs) are multidisciplinary research centers focused on bacterial pathogens for which antibiotic resistance poses a significant public health concern, as designated by the CDC’s 2019 Report on Antibiotic Resistance Threats in the United States. Each center brings together investigators from multiple disciplines to investigate non-antibiotic alternative treatment and preventive strategies, including bacteriophage, monoclonal antibodies, ligand mimetics, and defined microbial consortia; poorly understood resistance mechanisms contributing to bacterial persistence and antibiotic treatment failure; and identification and validation of novel bacterial targets for antibiotic intervention.

Project NextGen

Led by NIAID and the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Administration for Strategic Preparedness and Response (ASPR), Project NextGen is a coordinated effort where the federal government works with the private sector to advance the pipeline of new, innovative vaccines and therapeutics from labs into clinical trials with the intent to transition to the private sector later stage development and potential U.S.